# LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer

> **NCT06876675** · — · ENROLLING_BY_INVITATION · sponsor: **Peking University Third Hospital** · enrollment: 167 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer
- Hyperlipidemia

## Interventions

- **DRUG:** Lorlatinib

## Key facts

- **NCT ID:** NCT06876675
- **Lead sponsor:** Peking University Third Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-10-15
- **Primary completion:** 2025-09
- **Final completion:** 2029-08
- **Target enrollment:** 167 (ESTIMATED)
- **Last updated:** 2025-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06876675

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06876675, "LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06876675. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*